NEW YORK (GenomeWeb News) – Waters said today that the Chinese Food and Drug Administration has approved registration of its Acquity UPLC TQD system for sale as a medical device for routine diagnostic applications and neonatal metabolites disease screening.

The device is the second of Waters to receive Chinese approval for in vitro diagnostic applications. In 2008, the CFDA approved a neonatal screening test on the company's Quattro micro mass spec.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.